Associated Papers
Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis.
Téllez Castillo N et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Gene duplication is associated with gene diversification and potential neofunctionalization in lung cancer evolution.
Ashford P et al.
Genome Research, 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
Rakaee M et al.
Jama Oncology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The Correlation Among PD-L1 Expression and the Driver Genes Status in Malignant Pleural Effusion of Lung Adenocarcinoma.
Wang R et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.
Azuma K et al.
Cancer Treatment and Research Communications, 2026
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.
Saito Y et al.
Nature Medicine, 2026
Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report.
Zhu X et al.
Oncology Letters, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma.
Shang J et al.
Cell Discovery, 2026
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.
Zhang Y et al.
Nature Communications, 2026
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients.
Abdelmaksoud-Dammak R et al.
Molecular Biology Reports, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study.
Braschel C et al.
Cancers, 2026
Detecting EGFR Gene Mutations on a Nanobioarray Chip.
Xu F et al.
Biomedicines, 2026
Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.
Deng F et al.
Cancers, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Application of pleural effusion cell blocks for immunohistochemistry and EGFR gene mutation testing for advanced lung cancer.
Zhao S et al.
Experimental and Therapeutic Medicine, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Tomasini P et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2026
A Case of Lung Adenocarcinoma With Concurrent EGFR Mutation and ALK Fusion Combined With Literature Review.
Chen Y et al.
Clinical Case Reports, 2026
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.
Carbone M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.
Behera R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk.
Melikova LA et al.
Cancer Prevention Research (philadelphia, Pa.), 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX.
Chen KT et al.
The Oncologist, 2025
Germline EGFR T790M in Lung Cancer: Prevalence, Clinical Impact, and Implications for Hereditary Risk.
Melikova LA et al.
Cancer Prevention Research (philadelphia, Pa.), 2025
Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment.
Chen Z et al.
Annals of Medicine, 2025
Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation.
Sonoda D et al.
Annals of Surgical Oncology, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.
Chen ACC et al.
Lung Cancer (amsterdam, Netherlands), 2025
Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib.
Kagawa K et al.
Cancer Reports (hoboken, N.j.), 2025
Unveiling the clinical impact of plasma-only mutations in non-small cell lung cancer: a Korean multicenter experience.
Lee JW et al.
Translational Lung Cancer Research, 2025
Immunotherapy in EGFR-mutant non-small cell lung cancer.
Wang L et al.
Clinical and Experimental Medicine, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population.
Lee JY et al.
Npj Precision Oncology, 2025
Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy.
Nieva JJ et al.
Oncology and Therapy, 2025
Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.
Shenoy PV et al.
Cancer Metastasis Reviews, 2025
Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Lee PH et al.
Anti-cancer Drugs, 2025
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer.
Vakkalagadda CV et al.
Clinical Lung Cancer, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
van der Wel JWT et al.
Lung Cancer (amsterdam, Netherlands), 2025
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.
Wu X et al.
Lung Cancer (amsterdam, Netherlands), 2025
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults.
Abele M et al.
Lung Cancer (amsterdam, Netherlands), 2025
Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.
Lin F et al.
Genes, Chromosomes & Cancer, 2025